Aripiprazole-induced parkinsonism

Ashish Sharma, James H. Sorrell

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of ≥ 75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.

Original languageEnglish (US)
Pages (from-to)127-129
Number of pages3
JournalInternational Clinical Psychopharmacology
Volume21
Issue number2
DOIs
StatePublished - Mar 1 2006

Fingerprint

Parkinsonian Disorders
Antipsychotic Agents
Dopamine Receptors
Positron-Emission Tomography
Dopamine
Serotonin
Aripiprazole
Pharmacology

Keywords

  • Aripiprazole
  • EPS
  • Parkinsonism

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Aripiprazole-induced parkinsonism. / Sharma, Ashish; Sorrell, James H.

In: International Clinical Psychopharmacology, Vol. 21, No. 2, 01.03.2006, p. 127-129.

Research output: Contribution to journalArticle

Sharma, Ashish ; Sorrell, James H. / Aripiprazole-induced parkinsonism. In: International Clinical Psychopharmacology. 2006 ; Vol. 21, No. 2. pp. 127-129.
@article{275a21e8e1c142879279718aa0b9bc98,
title = "Aripiprazole-induced parkinsonism",
abstract = "Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70{\%} blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of ≥ 75-80{\%} results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.",
keywords = "Aripiprazole, EPS, Parkinsonism",
author = "Ashish Sharma and Sorrell, {James H.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.yic.0000185025.40656.30",
language = "English (US)",
volume = "21",
pages = "127--129",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Aripiprazole-induced parkinsonism

AU - Sharma, Ashish

AU - Sorrell, James H.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of ≥ 75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.

AB - Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of ≥ 75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.

KW - Aripiprazole

KW - EPS

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=33645223714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645223714&partnerID=8YFLogxK

U2 - 10.1097/01.yic.0000185025.40656.30

DO - 10.1097/01.yic.0000185025.40656.30

M3 - Article

VL - 21

SP - 127

EP - 129

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 2

ER -